1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Longevity Health Holdings Inc.

Longevity Health Holdings Inc.

XAGEW
Longevity Health Holdings Inc.US flagNASDAQ Global Market
0.01
USD
+0.00
- -
8,991.00Market Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
2
2
Operating Margin (%)
- -
- -
- -
-9,933.82
-371.58
-386.2
Depreciation Expense
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-6
-9
-15
-10
-7
-7
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-20,605.47
-361
-380.73
Working Capital
-16
-7
24
-5
-6
-7
LT Debt
1
1
1
- -
- -
- -
Total Equity
-30
-38
25
-5
-6
-7
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
2
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
3
2
1
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
1
Total Current Liabilities
7
8
8
Payables & Accruals
6
7
7
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
24.49%
Free Cash Flow
- -
- -
-14.12%
Net Income, GAAP
- -
- -
-33.4%
Sales/Revenue/Turnover
- -
- -
3,701.44%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
1
1
- -
- -
2
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Janakiram Ajjarapu
Full Time Employees
15
Sector
Healthcare
Industry
Biotechnology
Address
2403 Sidney Street Pittsburgh PA United States of America 15203
IPO Date
Mar 20, 2025
CIK
0001842939
Website
carmellcosmetics.com
Similar Companies
Apexigen, Inc. (APGNW)
Bavarian Nordic A/S (BVNKF)
Invex Therapeutics Ltd (IXC.AX)
MDEChem, Inc. (MDKM)
Calithera Biosciences, Inc. (CALA)
Noxopharm Limited (NOXOF)
Business
Longevity Health Holdings, Inc. (XAGEW) operates as a bio-aesthetics company focused on developing, manufacturing, and marketing regenerative skincare and haircare products that leverage human-derived bioactive materials to promote skin and hair health. Founded in 2008 and headquartered in Pittsburgh, Pennsylvania, the company offers Carmell Secretome, a blend of growth factors, proteins, peptides, and bio-lipids derived from allogeneic human platelets; Elevai Exosomes, containing growth factors, cytokines, peptides, and other molecules involved in natural healing; and a microemulsion delivery system enabling lipophilic and hydrophilic ingredients without common harmful excipients. It serves dermatologists, plastic surgeons, and consumers primarily in the United States through its carmellcosmetics.com platform and physician networks. In March 2025, the company, formerly Carmell Corporation, rebranded to Longevity Health Holdings, Inc. to emphasize expansion into longevity and healthy aging segments including diagnostics and nutrition, while acquiring Elevai Skincare, Inc. in January 2025 to integrate stem cell exosome technology and boost sales. Recent developments include executing a merger agreement with 20/20 BioLabs in April 2025 to double fiscal 2025 revenue forecasts, raising $1.96 million via at-the-market equity sales in May 2025 to extend cash runway, announcing a $59 million all-stock merger with THPlasma (True Health Inc.) in July 2025 to enter plasma-derived therapeutics with $100 million in sales offtake agreements, and planning Q2 2025 launches of Hair Growth Serum, Soapless Facial Cleanser, Undereye Crème, and VSA Toning Moisturizer.